Identifying genes whose dierential expression aect the survival of patients after primary tumor surgery is a major aim of clinical cancer research. To address this issue we combined rapid bioinformatic search algorithms with quantitative RT ± PCR in a panel of clearly de®ned cases of colorectal carcinomas with detailed patient histories. Search algorithms were written that identi®ed Expressed Sequence Tags (ESTs) from the Unigene EST collection of putative open reading frames (ORFs). Expression ratios of healthy to cancerous tissue of each Unigene ORF were calculated. The ®rst 35 candidates arising from bioinformatic searches were examined for mRNA expression in a panel of 20 well documented cases of colon cancer. Four of these 35 genes showed signi®cant correlations with histopathological parameters. Therefore, their expression was further analysed by quantitative RT ± PCR in a larger patient cohort. Kaplan-Meier/log rank statistical tests of up to 49 patients in three of the four genes demonstrated signi®cant association of gene expression with poor survival. All four genes demonstrated a strong association with metastatic tumor progression. Expression of the genes was localized to epithelial cells by in-situ hybridization. Oncogene (2001) 20, 4581 ± 4585.
Patient survival after initial surgical resection of colon cancer is poor. In the recent EUROCARE study of colon cancer, estimated disease free survival was 38% (Verdecchia et al., 1998) . In the USA almost 50% of patients diagnosed annually with colorectal cancer will eventually die of their disease. In a large number of cases malignant cancer is preceded by a wellrecognized pre-malignant lesion. Therefore identi®ca-tion of diagnostic markers of malignancy have the possibility to impact strongly on overall survival chances. In addition, postoperative diagnosis using markers of malignancy can enable better identi®cation of metastatic spread to the lymph nodes and other distant sites (Steinberg et al., 1986) . Finally in an age of increased budget constraints, ®nding markers of malignancy that could dictate postoperative treatment in a more cost-eective manner are very important (Gazelle et al., 2000) . A number of gene markers of colon carcinoma have been identi®ed and used with varying degrees of success (Kim et al., 2000; McLeod and Murray, 1999) . These include the well studied carcinoembryonic antigen CEA, and to a lesser extent mutated p53 and K-ras (Halaschek-Wiener et al., 2000) . To ®nd novel prognostic marker genes we decided to search the new high throughput data generated by the human EST data base. The human EST data base is growing rapidly with almost 3.5 million human ESTs deposited (April 2001, NCBI dbEST) . This large random cDNA collection represents many tissue types, alternative splice forms and developmental time points. A number of studies have used public or private EST data to study tissue expression pro®les`in silico' although as yet not directly applied to clinical data (Lal et al., 1999; Schmitt et al., 1999) . The aim of this study was to combine this new wealth of EST expression data with detailed information collected from a colon tumor tissue bank. Using this combined data we were able to directly test sequences for their clinical relevance in terms of patient survival and or metastatic spread.
Our in-house software examined the Unigene collection of putative ORFs. The Unigene project tries to cluster ESTs into putative ORFs (Boguski and Schuler, 1995) . The ESTs making up a cluster can be used to screen for tissue expression. In-house software examined the Unigene collection of EST clusters for tissue expression. The software identi®ed those Unigene clusters which were dierentially expressed in various cancer tissue types with a ratio of cancer to normal tissues of 1.5 or greater. Each cluster had a minimum of 30 ESTs. From within this collection, clusters were chosen that were expressed in colon tissues. Software written to compare tissue expression was written in C and Perl. Our algorithm identi®ed 740 Unigenes clusters dierentially expressed in various cancer tissue types. From within this list 583 were identi®ed with expression in colon tumor (http:// rhodos.bioinf.mdc-berlin.de/cancer/result3.html).
In a ®rst round rapid screen for over or under expression, 35 candidate sequences were tested by semiquantitative duplex RT ± PCR (Schneider et al., 2001) in a panel of 20 well documented cases. Four of the candidates showing dierential expression in this screen were examined by quantitative real-time RT ± PCR in up to 49 well de®ned cases with colon cancer. (Taqman method, Table 1 ). The four genes were tested for clinical relevance in terms of metastatic spread and patient survival (Figure 1) . The cellular location of EST expression of each gene was determined by in situ hybridization. All four genes showed clear expression in colonic tumor and/or epithelial cells (http://rhodos.-bioinf.mdc-berlin.de/cancer/experimental).
Unigene cluster HS1 (Unigene HS169395)
In the ®rst round duplex RT ± PCR screen 12 out of 20 carcinoma tissues showed an HS1 overexpression. Slight expression of HS1 was also detected in RNA preparations from healthy donors. Taqman quantitative RT ± PCR from 49 patients was carried out (Table  1) . Statistical analysis of the data showed a signi®cant correlation of HS1 expression with the presence of distant metastases M (P=0.0001). HS1 correlated signi®cantly with poor survival of patients (P=0.0106, Figure 1a) . A cut-o value of 10% (per cent of expression with respect to û-actin expression) was used to divide patients in high (number of cases, n=25) and low expressing (n=24) groups for the survival analysis. The clustering of 145 ESTs in the Unigene cluster of HS1 produced a consensus sequence of approximately 1400 bps. Matching ESTs were traced from source and accession numbers searched for corresponding 5' (r.1 image consortium ESTs) or 3' (s.1) end EST clones that were not matched to the 1400 bp sequence. In this way ESTs from the same original cDNA were identi®ed. By RACE-analysis and subsequent data bank searches we were able to expand a b c Figure 1 Overall survival analysis of patients. (a) With regard to HS1 mRNA-expression (n=49). Survival curves were obtained according to Kaplan ± Meier and the signi®cance of the dierences was assessed by the log-rank test. A cut o value of 10% (per cent of expression with respect to û-actin expression) was used to divide patients in high (n=25) and low expressing (n=24) groups for the survival analysis. HS1 expression was found to be highly associated (log rank, P=0.0106) with patient survival. (b) With regard to HS3 mRNA-expression (n=40). Survival curves were obtained according to Kaplan ± Meier and the signi®cance of the dierences was assessed by the log-rank test. A cut o value of 2.1% (per cent of expression with respect to û-actin expression) was used to divide patients in high (n=20) and low expressing (n=20) groups for the survival analysis. HS3 expression was found to be highly associated (log rank, P=0.0111) with patient survival. (c) With regard to Gene21 mRNA-expression (n=42). Survival curves were obtained according to Kaplan ± Meier and the signi®cance of the dierences was assessed by the log-rank test. Cases without expression of Gene21 (n=19) were discriminated from cases with detectable expression (n=23). Gene21 expression was found to be highly associated (log rank, P=0.0143) with patient survival Only microdissected carcinoma tissue from cryostat sections of a selected panel of well-documented subsequent cases of colorectal carcinoma tissue and corresponding normal tissue available in the tumor tissue bank of the Robert-RoÈ ssle-clinic, Berlin-Buch was examined. RNA was extracted using RNeasy (Qiagen, Hilden, Germany). Quantitative RT ± PCR (Taqman method) was used for determinations of mRNA expression. As positive controls, appropriate tumor cell lines were used. All ampli®ed reaction products were sequenced. Kaplan-Meier survival curves were generated and the log rank statistical test was used to evaluate the signi®cance of gene expression with patient survival. Several clinico-pathological parameters including metastatic lymph nodes and distant metastatic spread were tested with both the Kruskal ± Wallis and Mann ± Whitney test for association with dierential gene expression. For details of the experimental methods see (http://rhodos.bioinf.mdcberlin.de/cancer/experimental). Numbers given in Table 1 represent the mean percentage of¯uorescence of the same vs¯uorescence of b-actin control according to Taqman RT ± PCR, except in the case of Gene21 where a qualitative distinction was made between detectable (1) or no expression (0 means less than 1%). The deviation between three independent measurements of mRNA expression was always less than 5%. Carcinomas were classi®ed and characterized according to the WHO/UICC system. Abbreviations: T, invasiveness; N, metastasis to regional lymph nodes; M, formation of distant metastases; G, grading; L, lymphatic in®ltration; V, venous in®ltration; survival, postsurgical survival in months; survival+, patient still alive; HS1 M, expression of HS1 in normal mucosa, HS1 T, expression of HS1 in tumor tissue; the same is valid for HS2,3 and Gene21 in human embryonic tissue (unpublished, gi 10433397).
From the deduced protein sequence we calculated a peptide sequence, which is now being used for the production of antibodies.
Unigene cluster HS2 (HS127144)
In the ®rst round screen nine of the 20 carcinomas tissues showed over expression of HS2. Again only slight expression of the sequence was seen in the RNA preparation from healthy donor tissue. Taqman quantitative RT ± PCR of 40 patients showed that over expression of HS2 in tumors vs normal mucosa (P=0.001) correlated with the formation of distant metastases M (P=0.005) and lymph node metastases pN (P=0.04). However there was no signi®cant association between HS2 expression and survival of patients (P=0.09). Clustering of ESTs from the Unigene set of HS2 produced no signi®cant gains to searching databases with a single EST from the cluster. The gene product from this cluster remains unknown without a signi®cant size open reading frame and may well be the 3' UTR of this gene. To clarify the role of this gene we are at present testing a larger colon tumor collection to gain a better measure of statistical signi®cance for each parameter.
Unigene cluster HS3 (HS132793)
Taqman quantitative RT ± PCR of 40 patients showed an over expression of HS3 in tumors vs normal mucosa (P=0.016) and a signi®cant correlation with patient survival (P=0.0111, Figure 1b) . A cut o value of 2.1% (per cent of expression with respect to û-actin expression) was used to divide patients in high (n=20) and low expressing (n=20) groups for the survival analysis. Although the association of HS3 gene expression and the formation of distant metastases M (P=0.169) and lymph node metastasis pN (P=0.064) fell below the 0.05 signi®cance threshold, in both cases the trends seem to support dierential expression. At present HS3 remains without function. HS3 as well the other three candidates will be tested with a larger set of patient tumors to clarify the situation.
Gene 21
The sequence for gene 21 was submitted to the public data base as a direct entry without formal publication (gi AAC62535). Interestingly, although quantitative RT ± PCR was performed on tumor samples, many patients showed a complete lack of expression of this gene. Lack of expression of this gene was highly associated (P=0.0143, Figure 1c ) with patient survival, formation of lymph node metastases pN (P=0.002), dierentiation G (P=0.03) and slightly associated with the presence of distant metastases M (P=0.077). Gene 21 was directly submitted to GenBank under the title of candidate tumor suppressor gene located on 3p21.3 small cell lung cancer homozygous deletion region (Minna, JD and Lerman, MI). The lack of expression of this gene in colon tumors found in this study and the signi®cant association with poor patient survival would also ®t a tumor suppressor model for this gene. Thus, using this approach we identi®ed four genes with direct clinical relevance either to patient survival or to the progression of the tumor to high grade metastatic type or both. The aim of the present study was to show that this new approach of combining database screening with laboratory methods has the potential to identify novel genes that are involved in colon carcinoma or are indicative of a progression to colon carcinoma. Further experiments on a larger cohort of patients are necessary to con®rm the prognostic value of the putative marker genes. The main advantage of the described method is its speed and simplicity. Finding dierentially expressed genes using dierential display of cDNA libraries is time consuming and expensive. Microarray techniques are at present prohibitively expensive for many labs. Our bioinformatic method is free and simply uses the large collection of gene expression data already generated in the public domain. In future the bioinformatic method will be useful for the design of microarrays. Already the present global EST information in combination with microarray data should give us greater con®dence in the results derived from any single microarray experiment. The EST data base is expanding rapidly, this should both increase the number of novel genes found to be dierentially expressed and add new tissue type data to those already found. Due to the fact that our search method looks for dierential expression of genes in cancer in general, it can be universally applied to cover any other type of cancer. The only limiting factor is the representation of the cancer tissue type in the public EST database. In conclusion we demonstrate with the large collection of new EST expression data, simple bioinformatics and quantitative RT ± PCR, that it is possible to successfully identify genes that play a direct role in the survival of patients with colon cancer.
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